Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility

[1]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[2]  J. M. Lee,et al.  eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration , 2007, Oncogene.

[3]  K. Watabe,et al.  Roles of AKT signal in breast cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[4]  N. Hay,et al.  The two TORCs and Akt. , 2007, Developmental cell.

[5]  Thomas D. Wu,et al.  Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer , 2007, Breast Cancer Research and Treatment.

[6]  C. J. Roberts,et al.  Developing gene expression signatures of pathway deregulation in tumors , 2006, Molecular Cancer Therapeutics.

[7]  A. Toker,et al.  Akt signaling and cancer: surviving but not moving on. , 2006, Cancer research.

[8]  A. Toker,et al.  Akt/PKB Signaling in Cancer: A Function in Cell Motility and Invasion , 2006, Cell cycle.

[9]  Hong Liu,et al.  Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Lau,et al.  Identification of elongation factor 1α as a potential associated binding partner for Akt2 , 2006, Molecular and Cellular Biochemistry.

[11]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[12]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[13]  Naomi R Wray,et al.  Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours , 2005, BMC Cancer.

[14]  E. Yorida,et al.  Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells , 2005, Oncogene.

[15]  C. Lindsley,et al.  Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. , 2005, Molecular cancer therapeutics.

[16]  A. Kral,et al.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .

[17]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[18]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[19]  G. Nicolson,et al.  Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma , 2004, Breast Cancer Research and Treatment.

[20]  Jonathan M. Lee.  Reproductive Biology and Endocrinology Open Access the Role of Protein Elongation Factor Eef1a2 in Ovarian Cancer 20q Gene Amplification and Ovarian Cancer , 2022 .

[21]  Jonathan M. Lee,et al.  Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis , 2003, Journal of Molecular Medicine.

[22]  Alfonso Bellacosa,et al.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.

[23]  C. Proud,et al.  Regulation of peptide-chain elongation in mammalian cells. , 2002, European journal of biochemistry.

[24]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[25]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[26]  J. Testa,et al.  AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.

[27]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[28]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[30]  J. Segall,et al.  Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. , 1996, Journal of cell science.

[31]  J. Condeelis.  Elongation factor 1α, translation and the cytoskeleton , 1995 .

[32]  J. Condeelis.  Elongation factor 1 alpha, translation and the cytoskeleton. , 1995, Trends in biochemical sciences.

[33]  B. Clark,et al.  Tissue‐dependent variation in the expression of elongation factor‐1α isoforms: Isolation and characterisation of a cDNA encoding a novel variant of human elongation‐factor 1α , 1993 .

[34]  D. Hardie.  Protein phosphorylation: a practical approach , 1993 .

[35]  B. Clark,et al.  Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. , 1993, European journal of biochemistry.

[36]  J. Condeelis,et al.  Identification of an actin-binding protein from Dictyostelium as elongation factor 1a , 1990, Nature.